Minhai COVID-19 vaccine
Vaccine against COVID-19
From Wikipedia, the free encyclopedia
Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | KCONVAC (Chinese: 可维克; pinyin: Kěwéikè) |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
Clinical trials
In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]
In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]
Children and adolescents trials
In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]
In September, KCONVAC started phase II trials with 480 participants in China.[5]
Authorizations
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]
.svg){kind=small}
.png){kind=small}